Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
Type:
Grant
Filed:
May 15, 2003
Date of Patent:
January 10, 2006
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman